StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock.
Moleculin Biotech Trading Up 9.0 %
Shares of Moleculin Biotech stock opened at $2.55 on Tuesday. Moleculin Biotech has a 52-week low of $2.12 and a 52-week high of $15.75. The company has a 50 day moving average of $2.50 and a 200 day moving average of $3.37.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($2.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.13). On average, research analysts predict that Moleculin Biotech will post -8.6 EPS for the current fiscal year.
Institutional Inflows and Outflows
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
See Also
- Five stocks we like better than Moleculin Biotech
- Best Aerospace Stocks Investing
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- What Are the U.K. Market Holidays? How to Invest and Trade
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- How to Find Undervalued Stocks
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.